KLRS

Kalaris Therapeutics, Inc.
CAPPED RATING

Kalaris Therapeutics, Inc. (KLRS) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.0
EV / EBITDA 0.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -59.3%
Price Return 12M -67.3%
Catalyst Signal 0.00
Market Cap $39.5M
TTM Revenue N/A
Price / Sales N/A
ROE -97.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B+ (3.7) C- (2.1) D+ (1.7) D- (0.9) C+ (2.6) C (2.2)
2026-11-06 C+ (2.5) C- (2.1) D+ (1.8) D (1.2) C+ (2.7) C- (2.1)
2026-10-30 C+ (2.5) C- (2.1) D+ (1.8) D (1.3) C+ (2.7) C- (2.1)
2026-10-23 C+ (2.5) C- (2.1) D+ (1.8) D (1.2) C+ (2.6) C- (2.0)
2026-10-16 C+ (2.5) C- (2.1) D+ (1.8) D- (1.1) C+ (2.6) C- (2.0)
Page 1 of 4